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S U M M A R Y
Objective: To examine the risk factors of carbapenem non-susceptibility and mortality among children
with Acinetobacter baumannii bacteremia.
Methods: A retrospective chart review was conducted of 180 cases with A. baumannii bacteremia.
Results: The 30-day mortality risk of A. baumannii bacteremia was 26.1%. Carbapenem-non-susceptible
A. baumannii was identiﬁed in 51.7% of cases. Logistic regression analysis indicated that prematurity,
use of mechanical ventilation, and prior exposure to carbapenem antibiotics were independently
associated with carbapenem-non-susceptible A. baumannii bacteremia, with adjusted odds ratios
(aORs) and 95% conﬁdence intervals (CIs) of 3.36 (1.17–9.65), 5.59 (2.24–13.97), and 2.97 (1.01–8.77),
respectively. Further, carbapenem non-susceptibility, cancer-related neutropenia, organ dysfunction,
admission to the intensive care unit, catheter-related bacteremia, and treatment with sulbactam-
containing regimens were associated with mortality with aORs and 95% CIs of 4.76 (1.58–14.32), 4.54
(1.09–18.79), 25.95 (5.13–131.33), 3.53 (1.29–9.71), 0.25 (0.084–0.72), and 0.14 (0.046–0.45),
respectively.
Conclusions: The majority of A. baumannii bacteremia was caused by carbapenem-non-susceptible
strains with a high mortality rate. Carbapenem non-susceptibility, cancer-related neutropenia, the
presence of organ dysfunction, and admission to an intensive care unit were associated with an
increased mortality risk, whereas catheter-related bacteremia and treatment with a sulbactam-
containing regimen were associated with decreased mortality among children with A. baumannii
bacteremia.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The recent emergence of multidrug-resistant Gram-negative
enteric bacteria has become a major challenge to clinicians and
endangers the health of patients worldwide.1,2 Acinetobacter
baumannii is among the most troublesome pathogens and has been
implicated in several types of nosocomial infections due to its
seemingly endless capacity to acquire antimicrobial resistance
mechanisms.3 In addition to its ability to acquire substantial
resistance genes, its remarkable ability to adjust itself in the hospital
environment, thus further enhancing its widespread transmissibili-
ty, has resulted in A. baumannii becoming a leading pathogen of
nosocomial infection.4 With the increase in the rate of carbapenem
resistance in A. baumannii observed worldwide, it is becoming more
and more difﬁcult, if not impossible, to treat this pathogen due to our* Corresponding author. Tel.: +66 85 515 8299; fax: +66 2 354 8345.
E-mail addresses: waruneep@gmail.com, warunee@vandepitte.eu
(W. Punpanich).
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http://dx.doi.org/10.1016/j.ijid.2012.07.006restricted pharmaceutical and therapeutic armamentarium. The
existing literature provides substantial information regarding the
epidemiology, clinical characteristics, and outcome of A. baumannii
infection. However, most of the published studies have been
conducted in the adult population, mainly from Western countries.
Little information is available on the clinical outcome, antimicrobial
susceptibility pattern, risk factors for carbapenem non-susceptibility,
and risk factors for mortality of A. baumannii bacteremia in children
in less developed settings. The objective of this study was to
examine the clinical characteristics, outcomes, and antimicrobial
susceptibility patterns of blood stream infection due to A. baumannii
in hospitalized children.
Queen Sirikit National Institute of Child Health (QSNICH),
generally known as the Children’s Hospital, is a 426-bed,
university-afﬁliated urban teaching hospital in Bangkok, Thailand,
catering mainly to poor and underprivileged children. QSNICH
provides all levels of care from primary to tertiary, and receives
consultation and referral cases from neighboring provinces and
nationwide. The hospital currently handles approximately 350 000
outpatient and 15 000 inpatient cases annually.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of the study population
Characteristics (N = 180 unless otherwise speciﬁed) n (%)
Median age (IQR), months 4 (15.82)
Male gender 100 (55.6)
Median length of hospital stay prior to bacteremia
(IQR), days
8 (19.5)
Presence of any underlying disease 145 (80.6)
Prematurity/low birth weight 39 (21.7)
Congenital heart diseases 21 (11.7)
Malignancy 18 (10)
Congenital anomalies 13 (7.2)
Chronic lung disease 10 (5.6)
Chronic liver disease 8 (4.4)
Portal of entry (concomitant source of infection)
Respiratory tract 31 (17.2)
Central venous catheter 43 (23.9)
Wound 8 (4.4)
Unknown 98 (54.4)
Presence of organ dysfunction 101 (56.1)
Presence of SIRS 136 (75.6)
Use of mechanical ventilator 81 (45)
Prior receipt of antibiotics 121 (67.2)
ICU admission 61 (33.9)
Polymicrobial infection 34 (18.9)
Median WBC count (IQR), 109/l 11.7 (12.225)
Carbapenem non-susceptibility (N =176) 91 (51.7)
Septic shock 50 (27.8)
30-day mortality 47 (26.1)
In-hospital mortality 51 (28.3)
ICU, intensive care unit; IQR, interquartile range; SIRS, systemic inﬂammatory
response syndrome; WBC, white blood cell.
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The study was a retrospective case series analysis of children
and adolescents aged 0–18 years receiving care at QSNICH
between October 2005 and September 2010 with proven A.
baumannii bacteremia. The cases were identiﬁed in the QSNICH
Microbiology Laboratory database by searching for positive blood
cultures. The medical records of the cases were obtained for the
review from the medical record archives. Information on demo-
graphics, clinical outcomes, laboratory ﬁndings, and antimicrobial
susceptibility patterns of the A. baumannii were collected. Patients
were classiﬁed as having systemic inﬂammatory response
syndrome (SIRS) based on the criteria proposed by Goldstein et al.5
A. baumannii were isolated and identiﬁed from clinical speci-
mens by standard microbiological methods. Susceptibility testing
of A. baumannii isolates was conducted using the standard disk
diffusion method only. Antimicrobial agents included in the
susceptibility testing for A. baumannii at QSNICH included
amikacin, cefotaxime, ceftriaxone, ceftazidime, cefoperazone/
sulbactam, ciproﬂoxacin, co-trimoxazole, gentamicin, imipenem,
meropenem, netilmicin, and colistin. Ampicillin/sulbactam sus-
ceptibility was not part of routine susceptibility testing at our
center due to the lack of Sensi-Disc. Susceptibility breakpoints
were based on those deﬁned by the Clinical and Laboratory
Standards Institute (CLSI).6 Carbapenem-non-susceptible A. bau-
mannii was deﬁned as isolates that exhibited in vitro resistance
and/or intermediate resistance to imipenem and/or meropenem
based on the disk diffusion method. Given the lack of current
interpretative criteria for the disk diffusion testing of colistin
against A. baumannii, modiﬁed zone criteria for colistin were used
in this study in which susceptibility was determined by an
inhibition zone size of 11 mm.7,8
2.1. Statistical analysis
Continuous variables were generally presented in terms of the
mean and standard deviation. The median and interquartile range
(IQR) was used when they were not normally distributed.
Categorical variables were expressed as percentages. Comparisons
between clinical and laboratory characteristics were done using
the Student’s t-test or Mann–Whitney test for continuous
variables, as indicated, and the Chi-square test or Fisher’s exact
test for categorical variables, as appropriate. To identify the
independent risk factors of carbapenem non-susceptibility and
mortality for A. baumannii bacteremia, multivariable logistic
regression analyses using the backward likelihood ratio selection
method were employed to control for the effects of potential
confounding factors. A p-value of 0.05 was considered statisti-
cally signiﬁcant.
3. Results
A total of 180 cases of A. baumannii bacteremia were identiﬁed
among a total of 74 955 hospitalizations during the period
between October 2005 and September 2010, or approximately
2.4 episodes per 1000 hospitalized children. The median age (IQR)
was 4 (15.8) months. The male to female ratio was 1.25:1.
Neonates and infants accounted for approximately three-quarters
of the study population. The proportions of patients under 1
month, 12 months, and 24 months of age were 36.1%, 71.1%, and
86.1%, respectively.
3.1. Clinical characteristics
The baseline clinical and demographic characteristics of the
study population are presented in Table 1. The infection occurredafter a median (IQR) hospital stay of 8 (19.5) days. In all cases the
infections were nosocomially acquired; 33.9% were acquired in
intensive care units (ICU). Underlying diseases were identiﬁed in
145 cases (80.6%). Forty-four cases (24.4%) of A. baumannii
bacteremia were considered to be the result of a contaminant
rather than a causative pathogen of blood stream infection. Such
cases were deﬁned if there was an absence of clinical symptoms
compatible with SIRS during the time when the organism was
isolated from the blood. Of these 44 patients, 40 cases (90.9%)
resolved spontaneously, and three cases (6.8%) were associated
with intravascular catheterization.
3.2. Laboratory ﬁndings
The median (range) white blood cell count was 11.70
(0.13–96.09)  109 cells/l. Despite the invasive nature of the
illness, the white blood cell counts of 48.3% of the cases were
considered to be within normal limits (5–15  109 cells/l). In other
words, the sensitivity of this leukocyte count criterion in detecting
A. baumannii bacteremia was only 51.7%. In addition, in a subgroup
analysis of cases presenting with symptoms and signs compatible
with SIRS, the sensitivity of this criterion remained rather
low (60.4%).
A. baumannii was universally susceptible to colistin with a 100%
susceptibility rate, followed by cefoperazone/sulbactam (63.9%),
carbapenem (49.4%), amikacin (42.2%), and ceftazidime (40.6%). Of
note, carbapenem non-susceptibility was identiﬁed in up to 51.7%
of cases (n = 93). Factors associated with carbapenem non-
susceptibility based on univariate and multivariable analysis are
shown in Tables 2 and 3.
3.3. Clinical outcomes
Forty-three cases (23.9%) spontaneously resolved (deﬁned by
spontaneous defervescence plus negative blood culture prior to
proper antibiotic treatment). In-hospital death occurred for a total
Table 2
Univariate analysis of the clinical characteristics of patients with Acinetobacter baumannii bacteremia with and without carbapenem non-susceptibility
Characteristics Carbapenem susceptibility (N = 176), n (%)
Susceptible
(n = 85)
Non-susceptible
(n = 91)
p-Value
Median age (IQR), months 9 (28.86) 1 (7.57) <0.001a
Male (n = 99) 51 (60) 48 (52.7) 0.332
Presence of underlying disease (n = 142) 63 (74.1) 79 (86.8) 0.033
Malignancy with febrile neutropenia (n = 18) 11 (12.9) 7 (7.7) 0.251
Prematurity (n = 39) 9 (10.6) 30 (33.0) <0.001
Extremely low birth weight (n = 20) 3 (3.5) 17 (18.7) 0.002b
ICU admission (n = 61) 11 (12.9) 50 (54.9) <0.001
SIRS (n = 134) 49 (57.6) 85 (93.4) <0.001
Use of mechanical ventilation (n = 81) 13 (15.3) 68 (74.7) <0.001
CABSI (n = 41) 8 (9.4) 33 (36.3) <0.001
Polymicrobial bacteremia (n = 34) 17 (20) 17 (18.7) 0.825
Any organ dysfunction (n = 101) 30 (35.3) 71 (78.0) <0.001
Cardiovascular dysfunction (n = 50) 11 (12.9) 39 (42.9) <0.001
Respiratory dysfunction (n = 78) 20 (23.5) 58 (63.7) <0.001
Neurological dysfunction (n = 39) 8 (9.4) 31 (34.1) <0.001
Hematological dysfunction (n = 81) 21 (24.7) 60 (65.9) <0.001
Renal dysfunction (n = 12) 3 (3.5) 9 (9.9) 0.071b
Hepatic dysfunction (n = 25) 8 (9.4) 17 (18.7) 0.025
Previous treatment with 3rd generation cephalosporin (n = 43) 18 (21.2) 25 (27.5) 0.331
Previous treatment with sulbactamc (n = 10) 1 (1.2) 9 (9.9) 0.019b
Previous treatment with penicillin (n = 21) 6 (7.1) 15 (16.5) 0.054
Previous treatment with aminoglycoside (n = 27) 9 (10.6) 18 (19.8) 0.091
Previous treatment with carbapenem (n = 36) 8 (9.4) 28 (30.8) <0.001
Previous treatment with quinolone (n = 1) 0 (0) 1 (1.1) 1.0b
Abnormal WBC count (<5 or >15  109/l) (n = 93) 38 (44.7) 55 (60.4) 0.034
Median WBC count (IQR),  109/l (n = 170) 10.890 (9.465) 12.670 (12.9025) 0.467a
Median hospitalization before bacteremia (IQR), days (n = 176) 4 (17) 10 (19) <0.001a
Median length of stay (IQR), days (n = 176) 21 (55) 45 (70) 0.001a
CABSI, catheter-associated blood stream infection; ICU, intensive care unit; IQR, interquartile range; SIRS, systemic inﬂammatory response syndrome; WBC, white blood cell.
a Mann–Whitney test.
b Fisher’s exact test.
c Including cefoperazone/sulbactam or ampicillin/sulbactam.
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baumannii bacteremic episode was 26.1% (n = 47).
Eighty-ﬁve percent of cases who died within 30 days after the
bacteremic episode had an underlying disease. The most common
underlying chronic conditions among fatal cases were prematuri-
ty/low birth weight (27.7%), followed by congenital heart diseases
(11.7%), malignancy (10%), and liver diseases (6.4%). The 30-day
mortality rates among patients with A. baumannii bacteremia with
an unidentiﬁed source, bacteremia with pneumonia, bacteremia
with wound infection, and polymicrobial bacteremia were 31.9%,
44.7%, 4.3% and 27.7%, respectively.
3.4. Risk factors for severe disease
Univariate analysis indicated that neutropenic fever in children
with underlying malignancy, extremely low birth weight, ICU
admission, presence of SIRS, use of mechanical ventilation,Table 3
Logistic regression analysis of predictors of carbapenem non-susceptible Acineto-
bacter baumannii bacteremia
Predictors aOR 95% CI p-Value
SIRS 3.19 0.97–10.56 0.057
Use of mechanical ventilation 5.59 2.24–13.97 <0.001
Prematurity 3.36 1.17–9.65 0.024
Previous treatment with carbapenem 2.97 1.01–8.77 0.048
Previous treatment with sulbactama 4.30 0.47–39.56 0.197
Catheter-associated blood
stream infection
2.08 0.72–5.99 0.175
aOR, adjusted odds ratio; CI, conﬁdence interval; SIRS, systemic inﬂammatory
response syndrome.
a Including cefoperazone/sulbactam or ampicillin/sulbactam.presence of organ dysfunction, treatment with a carbapenem-
containing regimen, treatment with a sulbactam-containing
regimen (including cefoperazone/sulbactam and ampicillin/sul-
bactam), and carbapenem non-susceptibility were signiﬁcantly
associated with the 30-day mortality risk (Table 4). Logistic
regression analysis revealed that carbapenem non-susceptibility,
the presence of neutropenia in children with an underlying
malignancy, organ dysfunction, ICU admission, catheter-related
bacteremia, and treatment with a sulbactam-containing regimen
were independently associated with mortality, with adjusted
odds ratios and 95% conﬁdence intervals of 4.76 (1.58–14.32),
4.54 (1.09–18.79), 25.95 (5.13–131.33), 3.53 (1.29–9.71), 0.25
(0.084–0.72), and 0.14 (0.046–0.45), respectively (Table 5).
4. Discussion
Information on the burden of A. baumannii bacteremia in the
pediatric population is virtually non-existent. Existing reports
are mainly case reports and case series with relatively small
sample sizes.9 Our results showed that the burden of nosocomial A.
baumannii bacteremia among children was rather comparable to
that reported in the adult population in tertiary centers.10 Similar
to the existing literature, children with underlying debilitating
chronic conditions were over-represented in this study, reﬂecting
the opportunistic nature of this pathogen. This pathogen has been
implicated in nosocomial blood stream infections particularly
among those with an underlying debilitating chronic condition,
with isolated bacteremia (bacteremia without an identiﬁable
source) being the most common, followed by catheter-related
blood stream infections and bacteremia with concurrent lower
respiratory tract infections. In this study, we evaluated the
performance of the white blood cell count as a screening tool
Table 4
Univariate analysis of predictors of mortality in Acinetobacter baumannii bacteremia
Characteristics Mortality (N = 180), n (%)
Survived (n = 133) Died (n = 47) p-Value
Median age, months 4 4.3 0.626a
Male (n = 100) 69 (51.9) 31 (66.0) 0.095
Malignancy with febrile neutropenia (n = 18) 9 (6.8) 9 (19.1) 0.015
Prematurity (n = 39) 26 (19.5) 13 (27.7) 0.24
Extremely low birth weight (n = 20) 10 (7.5) 10 (21.3) 0.01
ICU admission (n = 61) 31 (23.3) 30 (63.8) <0.001
SIRS (n = 136) 90 (67.7) 46 (97.9) <0.001
Use of mechanical ventilation (n = 81) 45 (33.8) 36 (76.6) <0.001
Catheter-associated blood stream infection (n = 43) 34 (25.6) 9 (19.1) 0.37
Polymicrobial bacteremia (n = 34) 21 (15.8) 13 (27.7) 0.074
Any organ dysfunction (n = 101) 56 (42.1) 45 (95.7) <0.001
Cardiovascular dysfunction (n = 50) 11 (8.3) 39 (83.0) <0.001
Respiratory dysfunction (n = 78) 33 (24.8) 45 (95.7) <0.001
Neurological dysfunction (n = 39) 1 (0.8) 38 (80.9) <0.001
Hematological dysfunction (n = 81) 40 (30.1) 41 (87.2) <0.001
Renal dysfunction (n = 12) 2 (1.5) 10 (21.3) <0.001
Hepatic dysfunction (n = 25) 11 (8.3) 14 (29.8) <0.001
Carbapenem non-susceptibility (n = 91) 55 (41.4) 36 (76.6) <0.001
Treatment with carbapenem-containing regimen (n = 74) 47 (35.3) 27 (57.4) 0.008
Treatment with sulbactam-containing regimenb (n = 51) 43 (32.3) 8 (17.0) 0.045
Treatment with colistin-containing regimen (n = 39) 29 (21.8) 10 (21.3) 0.94
Median hospitalization before bacteremia, days 9 8 0.263a
ICU, intensive care unit; SIRS, systemic inﬂammatory response syndrome.
a Mann–Whitney test.
b Including cefoperazone/sulbactam or ampicillin/sulbactam.
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in this regard. In addition, most of the studies in pediatric
bacteremia have been conducted in children with community-
acquired rather than nosocomial infections. Similar to studies by
Bonsu et al. and Kuppermann et al.,11,12 the total peripheral
white blood cell count was a rather insensitive screening tool for
bacteremia in children. Therefore, the decision to obtain blood
cultures in children suspected of having bacteremia should not
rely on this test.
A nationwide survey of more than 300 hospitals in the USA found
that the rate of carbapenem resistance in A. baumannii increased
from 9% in 1995 to 40% in 2004.13A more recent survey from the USA
showed that this rate had increased to 49.2% in 2008.14 In our study,
the 51.7% rate of carbapenem-non-susceptible A. baumannii is
comparable to the 54.5% carbapenem non-susceptibility rate
reported in 2010 from the National Antimicrobial Resistance
Surveillance Center, Thailand.15 Previously identiﬁed risk factors
for multidrug-resistant and/or carbapenem-non-susceptible A.
baumannii invasive infection include recent ventilator-associated
pneumonia due to carbapenem-non-susceptible A. baumannii,16 the
presence of excess intravascular devices,16 ICU stay,17–19 duration of
hospital stay,17 prior receipt and number of prescribed antibiotics,20
prior treatment with a third-generation cephalosporin,21 carbape-
nem,19,21 or beta-lactam/beta-lactamase inhibitors,19 previousTable 5
Logistic regression analysis of predictors of mortality in Acinetobacter baumannii
bacteremia
Predictors aOR 95% CI p-Value
Carbapenem non-susceptibility 4.76 1.58–14.32 0.005
Cancer-related neutropenic fever 4.54 1.09–18.79 0.037
Presence of organ dysfunction 25.95 5.13–131.33 <0.001
ICU admission 3.53 1.29–9.71 0.014
Catheter-associated blood stream infection 0.25 0.084–0.72 0.011
Carbapenem-containing regimen 0.41 0.146–1.14 0.088
Sulbactam-containing regimena 0.14 0.046–0.45 0.001
aOR, adjusted odds ratio; CI, conﬁdence interval; ICU, intensive care unit.
a Including cefoperazone/sulbactam or ampicillin/sulbactam.colonization with A. baumannii,20 and a recent invasive procedure.20
Similar to existing reports, our study identiﬁed previous use of a
carbapenem19,22 and use of mechanical ventilation18 as indepen-
dent factors associated with carbapenem resistance. Further, we
identiﬁed prematurity as being an independent risk factor for
carbapenem-non-susceptible A. baumannii bacteremia.
Limited data are available on the outcomes of A. baumannii
bacteremia, especially that caused by multidrug-resistant and/or
carbapenem-non-susceptible strains in the pediatric population.
In addition, the mortality rate in A. baumannii bacteremia may not
reﬂect the case fatality rate of A. baumannii bacteremia due to the
presence of other contributing factors, especially underlying
debilitating conditions such as extremely low birth weight
neonates, congenital heart diseases, and cancer-related neutro-
penia. Nevertheless, the mortality rate among cases with A.
baumannii bacteremia (26.1%) in our study is at the lower end of
those reported for children and/or adults in Spain (34%)10 and
Korea (37.1%).23 Various predictors of fatality have been reported,
including age,19 disseminated intravascular coagulation,10 inap-
propriate or delayed antimicrobial treatment,10,19 severity of
organ failure,16,19 and increased white blood cell count at
bacteremia onset.16 We found that the strongest risk factor for
the 30-day mortality after A. baumannii bacteremia was the
presence of one or more organ dysfunction. Further, cancer-
related neutropenic fever and admission to the ICU each increased
the mortality risk by an approximate factor of four. In
parallel, evidence regarding the impact of multidrug resistance
and/or carbapenem non-susceptibility on the mortality from
A. baumannii bacteremia remains inconsistent. A few studies in
hospitalized22,24 and ICU16,25 patients did not ﬁnd a signiﬁcant
association between bacteremia caused by multidrug-resistant/
carbapenem-non-susceptible A. baumannii and mortality. On the
other hand, certain reports have shown multidrug-resistant A.
baumannii infection to be associated with a poor outcome,26–28
such as increased mortality,18,19,27 higher hospitalization costs,
and longer ICU and hospital stays.27 Our results demonstrated
that A. baumannii bacteremia caused by carbapenem-non-
susceptible strains exhibited a 4.8-times higher risk of mortality
W. Punpanich et al. / International Journal of Infectious Diseases 16 (2012) e811–e815 e815and a hospital stay twice the length of that of patients infected by
susceptible strains.
In our study, a striking feature was the association between
catheter-associated blood stream infection (CABSI) and a favorable
outcome. More than 90% of cases with CABSI caused by A.
baumannii had signs and symptoms compatible with SIRS.
Approximately two-thirds of CABSI cases responded promptly to
antibiotic treatment and 7.0% of cases resolved spontaneously after
catheter removal. In addition, A. baumannii CABSI was also
identiﬁed as a signiﬁcant predictor of a lower mortality compared
to non-CABSI. This ﬁnding may reﬂect the fact that the source of
infection could be removed relatively easily compared to those
who did not have any identiﬁable source or readily modiﬁable risk
factor.
The high rate of resistance towards third-generation cephalos-
porins, beta-lactam/beta-lactamase inhibitors, and carbapenems is
especially worrisome, as safe and effective therapeutic options
may be extremely limited, if not unavailable. As of the end of 2010,
none of our cases demonstrated colistin resistance. However, the
reader should bear in mind that the method for testing colistin
susceptibility was based on the disk diffusion method using the
cut-off point zone size of 11 mm to indicate susceptibility. This
method is not considered a gold standard; certain inconsistencies
were found when this method was compared with minimum
inhibitory concentration (MIC) measures based on standard agar
dilution29 and the Etest.30,31
A concurrent blood stream infection with other pathogens was
not uncommon and was found in 18.8% of cases in our series
compared to 27–35% reported from other studies.32–34 Of note,
such occurrences have not been described as being associated with
a worse outcome or mortality in the present or previous reports on
A. baumannii bacteremia.
In conclusion, carbapenem-non-susceptible strains were im-
plicated in the majority of hospital-acquired A. baumannii
bacteremia cases in children. Prematurity, the use of mechanical
ventilation, and prior exposure to carbapenem antibiotics were the
most important risk factors for carbapenem-non-susceptible A.
baumannii bacteremia. Carbapenem non-susceptibility, cancer-
related neutropenia, the presence of organ dysfunction, and ICU
admission were risk factors for mortality among children with A.
baumannii bacteremia. In contrast, catheter-related bacteremia
and treatment with a sulbactam-containing regimen were
associated with a decreased risk of mortality among these children.
Ethical approval: This study received ethical approval from
Queen Sirikit National Institute of Child Health (IRB approval
number 53-078).
Conﬂict of interest: No competing interest declared.
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